• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>InterCept

InterCept

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to Advance Its INTERCEPT Red Blood Cell Program

    Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to Advance Its INTERCEPT Red Blood Cell Program

  2. Fitch Affirms Memphis, TN GOs at 'AA-'; Outlook Remains Positive

    Fitch Affirms Memphis, TN GOs at 'AA-'; Outlook Remains Positive

  3. Chinese Jets Intercept U.S. Spy Plane Over East China Sea

    Chinese Jets Intercept U.S. Spy Plane Over East China Sea

  4. Intercept Pharma's new liver disease drug comes with hefty price tag: $70,000 a year

    Intercept Pharma's new liver disease drug comes with hefty price tag: $70,000 a year

  5. What's Behind Your Bond Fund's Returns?

    Bond funds' past performance isn't necessarily indicative of skill.

  6. Performance Evaluation Tool Kit

    The appropriate tools may help investors distinguish luck from skill. 

  7. Understanding Factor Models

    A primer on how linear factor models are used to look at fund manager performance. 

  8. Optimal Portfolios for the Long Run

    Our study shows that equity risk declines as time horizon expands.

  9. Secure Your Mobile Connections

    Public WiFi hotspots are everywhere, but advisors must take appropriate steps protect sensitive data when working from the road.

  10. The Predictive Power of Fair Value Estimates

    Investors would be smart to focus on stocks that trade at a discount to this metric.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.